Skip Navigation

Annals of Oncology 2007 18(6):1117; doi:10.1093/annonc/mdm184
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (21)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Rixe, O
Right arrow Articles by Izzedine, H
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rixe, O
Right arrow Articles by Izzedine, H
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2007 European Society for Medical Oncology

letters to the editor

Hypertension as a predictive factor of Sunitinib activity

The first 10% of the full text of this article appears below.

Sunitinib malate is a new reference standard for the treatment of metastatic renal cell carcinoma (mRCC) [1, 2]. Clinical or biological markers of activity and toxicity are warranted due to large variations in treatment response, as well as side effects. Hypertension is a major toxicity observed after . . . [Full Text of this Article]

O Rixe1, B Billemont1 and H Izzedine2,*

1 Departments of Medical Oncology, Pitie-Salpetriere Hospital, Paris, France
2 Departments of Nephrology, Pitie-Salpetriere Hospital, Paris, France

* Email: hassan.izzedine@psl.aphp.fr


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann OncolHome page
N. Steeghs, T. J. Rabelink, J. op 't Roodt, E. Batman, F. H. M. Cluitmans, N. I. Weijl, E. de Koning, and H. Gelderblom
Reversibility of capillary density after discontinuation of bevacizumab treatment
Ann. Onc., October 23, 2009; (2009) mdp417v1.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
E. T.H. Yeh and C. L. Bickford
Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management.
J. Am. Coll. Cardiol., June 16, 2009; 53(24): 2231 - 2247.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
H. Izzedine, S. Ederhy, F. Goldwasser, J. C. Soria, G. Milano, A. Cohen, D. Khayat, and J. P. Spano
Management of hypertension in angiogenesis inhibitor-treated patients
Ann. Onc., May 1, 2009; 20(5): 807 - 815.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
A. Ravaud and M. Sire
Arterial hypertension and clinical benefit of sunitinib, sorafenib and bevacizumab in first and second-line treatment of metastatic renal cell cancer
Ann. Onc., May 1, 2009; 20(5): 966 - 967.
[Full Text] [PDF]

Home page
 Ann OncolHome page
O. Mir, S. Ropert, J. Alexandre, and F. Goldwasser
Hypertension as a surrogate marker for the activity of anti-VEGF agents
Ann. Onc., May 1, 2009; 20(5): 967 - 970.
[Full Text] [PDF]

Home page
 Ann OncolHome page
P. Bono, H. Elfving, T. Utriainen, P. Osterlund, T. Saarto, T. Alanko, and H. Joensuu
Hypertension and clinical benefit of bevacizumab in the treatment of advanced renal cell carcinoma
Ann. Onc., February 1, 2009; 20(2): 393 - 394.
[Full Text] [PDF]

Home page
 Ann OncolHome page
J.-J. Mourad, G. des Guetz, H. Debbabi, and B. I. Levy
Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation
Ann. Onc., May 1, 2008; 19(5): 927 - 934.
[Abstract] [Full Text] [PDF]

Home page
 Journal of Pharmacy PracticeHome page
B. L. Frei and S. A. Soefje
A Review of the Cardiovascular Effects of Oncology Agents
Journal of Pharmacy Practice, April 1, 2008; 21(2): 146 - 158.
[Abstract] [PDF]